THORAZINE
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THORAZINE is an oral extended-release capsule approved in 1957 as an NDA small molecule. The generic name and specific mechanism of action are not provided in available data. This is a legacy product with a long commercial history in psychiatric and related indications.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30/100), signaling a likely contracting team focus on managed decline and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching lifecycle indicate this is a legacy product with contracting staffing needs. Career growth and advancement opportunities on this brand are minimal; professionals should expect portfolio rationalization and potential role consolidation.
Brand ManagerField Sales Representative
Worked on THORAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.